结直肠癌病人Vimentin表达的临床意义

doi:10.11904/j.issn.1002-3070.2015.04.007

摘要/Abstract

摘要： 目的探讨波形蛋白(Vimentin)表达与结直肠癌临床病理特征及预后的关系。方法采用免疫组化方法对189例经病理组织学证实的结直肠癌组织进行Vimentin表达情况检测,分析其与结直肠癌临床病理特征及预后的关系。结果 Vimentin阳性表达与淋巴结转移(pN分期,P=0.038)、TNM分期(P=0.024)显著相关。生存分析表明,Vimentin阳性表达与结直肠癌不良预后显著相关(P=0.016)。多因素分析发现,Vimentin表达是结直肠癌患者预后的一个独立因素(P=0.026)。结论 Vimentin阳性表达与淋巴结转移和TNM分期显著相关,是影响其预后的独立因素。

关键词: 波形蛋白, 结直肠癌, 上皮-间质转化, 预后

Abstract: Objective Vimentin is the major protein consisting of intermediate filaments in normal and neoplastic mesenchymal cells.It has been regarded as a marker of epithelial mesenchymal transition(EMT).However,little is known about colorectal cancer(CRC)with Vimentin expression as a marker of EMT and prognosis.Methods We investigated the expression of Vimentin in CRC tissues and determined the correlations between Vimentin expression patterns and clinicopathologic characteristics and prognosis in CRC.In total,189 patients diagnosed with CRC based on histopathological evaluation and those subjected to surgical resection at the Liaoning Province Cancer Hospital and Institute between 2000 and 2002 were examined.Immunohistochemical staining for Vimentin was performed for each specimen.Results Positive expression of Vimentin was significantly associated with the lymph node metastasis(pN stage,P=0.038),TNM stage(P=0.024).Survival analysis revealed that positive Vimentin expression was significantly related to poor prognosis(P=0.016).Multivariate analysis revealed that Vimentin expression was an independent prognostic factor for patient survival in colorectal cancer(P=0.026).Conclusion In Conclusion ,our data provide novel evidence for the clinical significance of Vimentin expression as potential predictive biomarkers for identifying patients with lymph node metastasis or poor prognosis in CRC.

Key words: Vimentin, Colorectal cancer, Epithelial-mesenchymal transition(EMT), Prognosis

中图分类号:

R735.3+4

高照华,张皓,石刚. 结直肠癌病人Vimentin表达的临床意义[J]. 实用肿瘤学杂志, 2015, 29(4): 319-326.

GAO Zhaohua,ZHANG Hao,SHI Gang. Clinical significance of Vimentin expression in patients with colorectal cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 319-326.

参考文献

1 Messerini L,Cianchi F,Cortesini C,et al.Incidence and prognostic significance of occult tumor cells in lymph nodes from patients with stage IIA colorectal carcinoma[J].Human Pathology,2006,37(10):1259-1267.
2 De Krijger I,Mekenkamp LJ,Punt CJ,et al.MicroRNAs in colorectal cancer metastasis[J].The Journal of Pathology,2011,224(4):438-447.
3 Iwatsuki M,Mimori K,Yokobori T,et al.Epithelial-mesenchymal transition in cancer development and its clinical significance[J].Cancer Science,2010,101(2):293-299.
4 Radisky DC.Epithelial-mesenchymal transition[J].Journal of Cell Science,2005,118(19):4325-4326.
5 Kalluri R,Weinberg RA.The basics of epithelial-mesenchymal transition[J].The Journal of Clinical Investigation,2009,119(6):1420-1428.
6 Mani SA,Guo W,Liao MJ,et al.The epithelial-mesenchymal transition generates cells with properties of stem cells[J].Cell,2008,133(4):704-715.
7 Tomaskovic-Crook E,Thompson EW,Thiery JP.Epithelial to mesenchymal transition and breast cancer[J].Breast Cancer Research,2009,11(6):213-222.
8 Gupta GP,Massague J.Cancer metastasis:building a framework[J].Cell,2006,127(4):679-695.
9 Steinert PM,Roop DR.Molecular and cellular biology of intermediate filaments[J].Annual Review of Biochemistry,1988,57:593-625.
10 Eckes B,Dogic D,Colucci-Guyon E,et al.Impaired mechanical stability,migration and contractile capacity in vimentin-deficient fibroblasts[J].Journal of Cell Science,1998,111(13):1897-1907.
11 Kang Y,Massague J.Epithelial-mesenchymal transitions:twist in development and metastasis[J].Cell,2004,118(3):277-279.
12 Thiery JP.Epithelial-mesenchymal transitions in tumour progression[J].Nature Reviews Cancer,2002,2(6):442-454.
13 Toiyama Y,Yasuda H,Saigusa S,et al.Increased expression of Slug and vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer[J].Carcinogenesis,2013,34(11):2548-2557.
14 Hamilton SR ALe.Pathology and genetics of tumours of the digestive system[M].France:IARC Press,2000:2.
15 Edge S BD,Compton C.AJCC cancer staging manual,7th ed[J].JAMA,2010,304(15):1726-1727.
16 Wu Y,Yamada S,Izumi H,et al.Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer[J].Journal of Surgical Oncology,2012,105(7):724-730.
17 Kouso H,Yano T,Maruyama R,et al.Differences in the expression of epithelial-mesenchymal transition related molecules between primary tumors and pulmonary metastatic tumors in colorectal cancer[J].Surgery Today,2013,43(1):73-80.
18 Grunert S,Jechlinger M,Beug H.Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis[J].Nature Reviews Molecular Cell Biology,2003,4(8):657-665.
19 Hugo H,Ackland ML,Blick T,et al.Epithelialmesenchymal and mesenchymalepithelial transitions in carcinoma progression[J].Journal of Cellular Physiology,2007,213(2):374-383.
20 Kokkinos MI,Wafai R,Wong MK,et al.Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo[J].Cells Tissues Organs,2007,185(1-3):191-203.
21 Ivaska J,Pallari HM,Nevo J,et al.Novel functions of vimentin in cell adhesion,migration,and signaling[J].Experimental Cell Research,2007,313(10):2050-2062.
22 Janosch P,Kieser A,Eulitz M,et al.The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments[J].FASEB J,2000,14(13):2008-2021.
23 Perlson E,Michaelevski I,Kowalsman N,et al.Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase[J].J Mol Biol,2006,364(5):938-944.
24 Liu LK,Jiang XY,Zhou XX,et al.Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas:correlation with the clinicopathological features and patient outcome[J].Mol Pathol,2010,23(2):213-224.
25 Fuchs IB,Lichtenegger W,Buehler H,et al.The prognostic significance of epithelial-mesenchymal transition in breast cancer[J].Anticancer Research,2002,22(6A):3415-3419.
26 Ngan CY,Yamamoto H,Seshimo I,et al.Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer[J].British Journal of Cancer,2007,96(6):986-992.
27 Dauphin M,Barbe C,Lemaire S,et al.Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas[J].Lung Cancer,2013,81(1):117-122.
28 Gilles C,Polette M,Piette J,et al.Vimentin expression in cervical carcinomas:association with invasive and migratory potential[J].The Journal of Pathology,1996,180(2):175-180.
29 Lang SH,Hyde C,Reid IN,et al.Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma[J].The Prostate,2002,52(4):253-263.
30 Logullo AF,Nonogaki S,Pasini FS,et al.Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma:association with progression[J].Oncology Reports,2010,23(2):313-320.
31 Yamashita N,Tokunaga E,Kitao H,et al.Vimentin as a poor prognostic factor for triple-negative breast cancer[J].J Cancer Res Clin Oncol,2013,139(5):739-746.
32 Karihtala P,Auvinen P,Kauppila S,et al.Vimentin,zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers:association with an aggressive tumour phenotype[J].Breast Cancer Res Treat,2013,138(1):81-90.
33 Sudo T,Iwaya T,Nishida N,et al.Expression of mesenchymal markers vimentin and fibronectin:the clinical significance in esophageal squamous cell carcinoma[J].Ann Surg Oncol,2013,20(Suppl 3):S324-335.
34 Jin H,Morohashi S,Sato F,et al.Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis[J].Biomed Res,2010,31(2):105-112.
35 Tobler NE,Detmar M.Tumor and lymph node lymphangiogenesis—impact on cancer metastasis[J].J Leukoc Biol,2006,80(4):691-696.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[6]	佟广海, 田洋, 吴华星. 脂质组学在结直肠癌研究中的应用[J]. 实用肿瘤学杂志, 2019, 33(2): 179-192.
[7]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[8]	刘恒辰, 张新宇. Toll样受体信号通路作为结直肠癌潜在治疗靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 188-192.
[9]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[10]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[11]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[12]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[13]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[14]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[15]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.